We are live on ! Find out more
AMAM

Ambrx Biopharma Inc
AMAM

Delisted

AMAM was delisted on the 6th of March, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Ambrx Biopharma Inc in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 68 → 0 (-68)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $913M → $0 (-$913M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 68

Holders
–
Holders Change
-68
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
68
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
DGM
Darwin Global Management
Jersey
-$238M
2
CAM
Cormorant Asset Management
Massachusetts
-$160M
3
PBA
Paradigm Biocapital Advisors
New York
-$62M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$60.4M
5
DTC
Deep Track Capital
Connecticut
-$52.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
DGM
1
Darwin Global Management
Jersey
– -$238M -16,688,636 Closed
CAM
2
Cormorant Asset Management
Massachusetts
– -$160M -11,231,000 Closed
PBA
3
Paradigm Biocapital Advisors
New York
– -$62M -4,352,689 Closed
D.E. Shaw & Co
4
D.E. Shaw & Co
New York
– -$60.4M -4,240,486 Closed
DTC
5
Deep Track Capital
Connecticut
– -$52.8M -3,710,412 Closed
NI
6
Nextech Invest
Switzerland
– -$44.6M -3,129,300 Closed
Balyasny Asset Management
7
Balyasny Asset Management
Illinois
– -$30.7M -2,154,700 Closed
LGM
8
Logos Global Management
California
– -$29.9M -2,100,000 Closed
VA
9
VR Adviser
New York
– -$29.5M -2,070,000 Closed
Citadel Advisors
10
Citadel Advisors
Florida
– -$29.1M -2,042,212 Closed
Fidelity Investments
11
Fidelity Investments
Massachusetts
– -$21M -1,474,258 Closed
Vanguard Group
12
Vanguard Group
Pennsylvania
– -$19.9M -1,399,642 Closed
WP
13
Woodline Partners
California
– -$17.9M -1,255,148 Closed
T. Rowe Price Associates
14
T. Rowe Price Associates
Maryland
– -$15.4M -1,084,247 Closed
WA
15
WuXi AppTec
China
– -$14.2M -1,000,000 Closed
BlackRock
16
BlackRock
New York
– -$7.14M -501,604 Closed
GTC
17
Ghost Tree Capital
New York
– -$6.76M -475,000 Closed
Millennium Management
18
Millennium Management
New York
– -$6.16M -432,709 Closed
Goldman Sachs
19
Goldman Sachs
New York
– -$5.69M -399,648 Closed
ABG
20
Ally Bridge Group
New York
– -$5.49M -385,383 Closed
Federated Hermes
21
Federated Hermes
Pennsylvania
– -$4.71M -330,949 Closed
Macquarie Group
22
Macquarie Group
Australia
– -$4.27M -300,000 Closed
O
23
OrbiMed
New York
– -$4.22M -296,000 Closed
Jane Street
24
Jane Street
New York
– -$4.21M -295,642 Closed
SSA
25
Schonfeld Strategic Advisors
New York
– -$3.76M -263,743 Closed
1
2 3

AMAM Hedge Fund Activity: Q1 2024 in Review

0 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q1 2024, worth a combined $0 — down 100% from $913M a quarter earlier.

Sellers outnumbered buyers: 68 funds closed out of AMAM and 0 opened new positions — a net loss of 68 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Darwin Global Management, exiting entirely with an estimated $238M sold.

  • 0 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q1 2024, down from 68 in Q4 2023.
  • Funds reported $0 of Ambrx Biopharma Inc stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Ambrx Biopharma Inc positions in Q1 2024 and 68 closed out, a net change of -68 holders.
  • The largest Ambrx Biopharma Inc seller in Q1 2024 was Darwin Global Management, an estimated $238M sold.

Based on aggregated 13F filings for Q1 2024.